Semi-annual Report for 2026
Filed with SSE · · 205 pages · Chinese
Suzhou Zelgen Biopharmaceuticals Co. Ltd. on 6ix
Earlier from Suzhou Zelgen Biopharmaceuticals
- Announcement on Abnormal Fluctuations in Stock Trading
- Announcement on Resolutions of the 2025 Annual General Meeting
- Announcement on Voluntary Disclosure of the Approval of Marketing Application for Ivarmacitinib Hydrochloride Tablets for he Treatment of Severe Alopecia Areata
- Announcement on Using Partial Temporarily Idle Raised Funds for Cash Management
- Announcement on Voluntary Disclosure of Clinical Data and Latest Progress of ZG005 and ZG006 Released at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
Later from Suzhou Zelgen Biopharmaceuticals
- Announcement on Voluntary Disclosure of Acceptance of the Supplemental New Drug Application for Human Thyrotropin Beta for Injection
- Announcement on Participating in the 2026 Semi-annual Collective Performance Briefing for the STAR Market Innovative Drug Industry
- Announcement on Voluntary Disclosure of the Acceptance of the New Drug Application for Gecacitinib Hydrochloride Tablets for the Treatment of Active Ankylosing Spondylitis
- (688266)"Suzhou Zelgen Biopharmaceuticals Co., Ltd."Announcement on Voluntary Disclosure of Receipt of Milestone Payment under the Global Strategic Collaboration and License Option Agreement with AbbVie in respect of ZG006
- (688266)"Suzhou Zelgen Biopharmaceuticals Co., Ltd."Announcement on Voluntary Disclosure of Completion of First Subject Enrollment in the Phase III Clinical Trial of ZG005 for Injection for the Treatment of First-Line Liver Cancer
Follow Suzhou Zelgen Biopharmaceuticals into a list and get an email when it puts out news.
Follow Suzhou Zelgen Biopharmaceuticals